Abelzeta Pharma Is A Global Clinical Stage Biopharmaceutical Company Dedicated To Developing Innovative T Cell Based Therapeutic Productsthe Company Focuses On Treating Cancer And Inflammatory And Immunological Diseases Using Its Proprietary Technologiesformerly Known As Cellular Biomedicine Groupabelzeta Has Made Significant Strides In Drug Development Since Treating Its First Oncology Patient In 2015 The Company Has A Robust Pipeline Of Candidates With Best In Class Potentialincluding Car T And Til Therapiesin 2023Abelzeta Licensed Two Cd20 Directed Autologous Car T Therapies To Janssen Biotechenhancing Collaboration With Multinational Pharmaceutical Companieswith Centers Of Excellence In Rockvillemarylandand Shanghaichinaabelzeta Is Strategically Positioned For Global Operations And Aims To Improve Patient Accessibility To Its Therapies
